Literature DB >> 25907834

Increased mannosylphosphorylation of N-glycans by heterologous expression of YlMPO1 in glyco-engineered Saccharomyces cerevisiae for mannose-6-phosphate modification.

Jin Young Gil1, Jeong-Nam Park2, Kyung Jin Lee1, Ji-Yeon Kang1, Yeong Hun Kim1, Seonghun Kim3, Sang-Yoon Kim1, Ohsuk Kwon3, Yong Taik Lim4, Hyun Ah Kang5, Doo-Byoung Oh6.   

Abstract

Mannosylphosphorylated N-glycans found in yeasts can be converted to those containing mannose-6-phosphate, which is a key factor for lysosomal targeting. In the traditional yeast Saccharomyces cerevisiae, both ScMNN4 and ScMNN6 genes are required for efficient mannosylphosphorylation. ScMnn4 protein has been known to be a positive regulator of ScMnn6p, a real enzyme for mannosylphosphorylation. On the other hand, YlMpo1p, a ScMnn4p homologue, mediates mannosylphosphorylation in Yarrowia lypolytica without the involvement of ScMnn6p homologues. In this study, we show that heterologous expression of YlMpo1p can perform and enhance mannosylphosphorylation in S. cerevisiae in the absence of ScMnn4p and ScMnn6p. Moreover, the level of mannosylphosphorylation of N-glycans enhanced by YlMpo1p overexpression is much higher than that with ScMnn4p overexpression, and this is highlighted further in Scmnn4- and Scmnn6-disrupted mutants. When YlMpo1p overexpression is applied to glyco-engineered S. cerevisiae in which the synthesis of immunogenic glycans is abolished, a great increase of bi-mannosylphosphorylated glycan is observed. Through an in vitro process involving the uncapping of the outer mannose residue, this bi-mannosylphosphorylated structure is changed to a bi-phosphorylated structure with high affinity for mannose-6-phosphate receptor. The superior ability of YlMpo1p to increase bi-mannosylphosphorylated glycan in yeast shows promise for the production of therapeutic enzymes with improved lysosomal targeting capability.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Enzyme replacement therapy; Lysosomal storage disease; Mannose-6-phosphate modification; Mannosylphosphorylation; ScMNN4; YlMPO1

Mesh:

Substances:

Year:  2015        PMID: 25907834     DOI: 10.1016/j.jbiotec.2015.04.007

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  6 in total

Review 1.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

2.  Mannose-6-phosphate glycan for lysosomal targeting: various applications from enzyme replacement therapy to lysosome-targeting chimeras.

Authors:  Jinho Seo; Doo-Byoung Oh
Journal:  Anim Cells Syst (Seoul)       Date:  2022-05-29       Impact factor: 2.398

Review 3.  Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases.

Authors:  Doo-Byoung Oh
Journal:  BMB Rep       Date:  2015-08       Impact factor: 4.778

4.  Lysosomal Targeting Enhancement by Conjugation of Glycopeptides Containing Mannose-6-phosphate Glycans Derived from Glyco-engineered Yeast.

Authors:  Ji-Yeon Kang; Keun Koo Shin; Ha Hyung Kim; Jeong-Ki Min; Eun Sun Ji; Jin Young Kim; Ohsuk Kwon; Doo-Byoung Oh
Journal:  Sci Rep       Date:  2018-06-07       Impact factor: 4.379

5.  Data for analysis of mannose-6-phosphate glycans labeled with fluorescent tags.

Authors:  Ji-Yeon Kang; Ohsuk Kwon; Jin Young Gil; Doo-Byoung Oh
Journal:  Data Brief       Date:  2016-04-23

6.  Phosphomannosylation and the Functional Analysis of the Extended Candida albicans MNN4-Like Gene Family.

Authors:  Roberto J González-Hernández; Kai Jin; Marco J Hernández-Chávez; Diana F Díaz-Jiménez; Elías Trujillo-Esquivel; Diana M Clavijo-Giraldo; Alma K Tamez-Castrellón; Bernardo Franco; Neil A R Gow; Héctor M Mora-Montes
Journal:  Front Microbiol       Date:  2017-11-06       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.